Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | EBP | Q15125 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5314906 | 0.98 | NCF1 (0.42) | NCF1GBA1CHRM5ADRA2CACHE | |
| SCHEMBL5316533 | 0.89 | NCF1 (0.41) | NCF1GBA1CHRM5ADRA2CACHE | |
| SCHEMBL5315253 | 0.89 | NCF1 (0.41) | NCF1GBA1CHRM5ADRA2CACHE | |
| SCHEMBL23015324 | 0.85 | NCF1 (0.52) | NCF1CHRM5ADRA2CACHECXCR4 | |
| Hydrochloric Acid SCHEMBL29653378 | 0.83 | NCF1 (0.50) | NCF1CHRM5ADRA2CACHECXCR4 | |
| SCHEMBL8235039 | 0.82 | GBA1 (0.41) | GBA1CHRM5ADRA2CACHEALDH1A1 | |
| SCHEMBL12188158 | 0.80 | ACHE (0.42) | GBA1CHRM5ADRA2CACHEALDH1A1 | |
| Hydrochloric Acid SCHEMBL28386967 | 0.80 | GBA1 (0.40) | GBA1CHRM5ADRA2CACHEALDH1A1 | |
| SCHEMBL20567 | 0.80 | — | — | |
| SCHEMBL7402141 | 0.79 | CHRM5 (0.64) | NCF1CHRM5ADRA2CACHECXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | claimed |
| US-9951045-B2 | Indazole compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| US-9951045-B2 | Indazole compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| US-9951045-B2 | Indazole compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| EP-3099675-B1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2018-02-14 | — | — | EP | disclosed |
| EP-3099675-B1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2018-02-14 | — | — | EP | disclosed |
| EP-3099675-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Suven Life Sciences Limited (IN) | 2016-12-07 | — | — | EP | disclosed |
| US-20160311797-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-10-27 | — | — | US | disclosed |
| US-20160311797-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-10-27 | — | — | US | disclosed |
| US-20160311797-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-10-27 | — | — | US | disclosed |
| WO-2010133306-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2010-11-25 | — | — | WO | disclosed |
| US-20070232657-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232657-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232657-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| WO-2007096352-A1 | 5-AMINO-6-BROMO-N-{ [1- (TETRAHYDR0-2H-PYRAN-4-YLMETHYL) -4-PIPERIDINYL] METHYL}-3, 4 -DIHYDRO-2H-CHROMENE-8-CARBOXAMIDE AS 5-HT4 RECEPTOR AGONIST | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007096352-A1 | 5-AMINO-6-BROMO-N-{ [1- (TETRAHYDR0-2H-PYRAN-4-YLMETHYL) -4-PIPERIDINYL] METHYL}-3, 4 -DIHYDRO-2H-CHROMENE-8-CARBOXAMIDE AS 5-HT4 RECEPTOR AGONIST | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007048643-A1 | NOVEL COMPOUND | GLAXO GROUP LIMITED (GB) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007048643-A1 | NOVEL COMPOUND | GLAXO GROUP LIMITED (GB) | 2007-05-03 | — | — | WO | disclosed |
| US-6951867-B2 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | NCF1 2405/4885GBA1 3352/4885CHRM5 598/4885 |
| US-20070232657-A1 | NOVEL COMPOUNDS | HTR4, HTR5A, HTR6 | NCF1 3438/4885GBA1 484/4885CHRM5 196/4885 |
| US-20160311797-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | NCF1 4170/4885GBA1 2289/4885CHRM5 154/4885 |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | NCF1 1324/4885GBA1 777/4885CHRM5 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.